Literature DB >> 11502840

Overexpression of CXC chemokines by an adrenocortical carcinoma: a novel clinical syndrome.

D E Schteingart1, T J Giordano, R S Benitez, M D Burdick, M N Starkman, D A Arenberg, R M Strieter.   

Abstract

A patient with adrenocortical carcinoma presented with fever, leukocytosis, and increased acute phase reactants. The tumor was infiltrated with neutrophils. Immunohistochemical staining of the tumor showed positive signal for epithelial neutrophil-activating protein-78, an angiogenic and chemotactic CXC chemokine. Conditioned medium from tumor-derived cells (RL-251) showed high concentration of IL-8, epithelial neutrophil-activating protein-78, Gro alpha, and Gro gamma, angiogenic CXC chemokines with a potential role in tumorigenesis. An adrenal cancer/severe combined immunodeficiency mouse chimera was developed. Mice grew tumors rapidly, and circulating levels of IL-8 and epithelial neutrophil-activating protein-78 were detected. In contrast, animals transplanted with NCI-H295 cells, a nonchemokine-secreting cell line, grew tumors more slowly and did not have detectable chemokine levels. Similar to the patient, mice with RL-251 tumors developed marked leukocytosis and neutrophilia, and their tumors were infiltrated with neutrophils. Mice were passively immunized with epithelial neutrophil-activating protein-78 antisera. A marked decrease in tumor growth was observed. Potential for chemokine production by other adrenocortical tumors was investigated by RT-PCR in archival material. Six of seven adrenal carcinomas and one of three adenomas had cDNA for IL-8; six of seven carcinomas and the three adenomas had cDNA for epithelial neutrophil-activating protein-78. We concluded that the clinical presentation of this case resulted from increased tumor production of chemotactic chemokines. Through their angiogenic and chemotactic properties these chemokines may play an important role in adrenal tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502840     DOI: 10.1210/jcem.86.8.7780

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Comparison of aldosterone production among human adrenocortical cell lines.

Authors:  T Wang; J G Rowland; J Parmar; M Nesterova; T Seki; W E Rainey
Journal:  Horm Metab Res       Date:  2012-01-20       Impact factor: 2.936

2.  Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma.

Authors:  Derek P Simon; Thomas J Giordano; Gary D Hammer
Journal:  Clin Cancer Res       Date:  2012-03-16       Impact factor: 12.531

Review 3.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 4.  Human adrenocortical carcinoma cell lines.

Authors:  Tao Wang; William E Rainey
Journal:  Mol Cell Endocrinol       Date:  2011-09-05       Impact factor: 4.102

5.  Severe Cholestatic Jaundice (Stauffer Syndrome) as a Rare Paraneoplastic Manifestation in Adrenocortical Carcinoma.

Authors:  Natia Murvelashvili; Patricio M Polanco; Sarah M Khorsand; Jorge A Marrero; Liwei Jia; Sasan Mirfakhraee; Tobias Else; Mouhammed Amir Habra; Suzanne Cole; Oksana Hamidi
Journal:  J Endocr Soc       Date:  2022-06-29

6.  Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

Authors:  Ferdous M Barlaskar; Aaron C Spalding; Joanne H Heaton; Rork Kuick; Alex C Kim; Dafydd G Thomas; Thomas J Giordano; Edgar Ben-Josef; Gary D Hammer
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

7.  Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma.

Authors:  Rui Kuai; Chitra Subramanian; Peter T White; Barbara N Timmermann; James J Moon; Mark S Cohen; Anna Schwendeman
Journal:  Int J Nanomedicine       Date:  2017-09-06

8.  Altered expression of the IGF2‑H19 locus and mitochondrial respiratory complexes in adrenocortical carcinoma.

Authors:  Patrick Scicluna; Stefano Caramuta; Hanna Kjellin; Cheng Xu; Robin Fröbom; Monira Akhtar; Jiwei Gao; Hao Shi; Magnus Kjellman; Malin Almgren; Anders Höög; Jan Zedenius; Tomas J Ekström; Robert Bränström; Weng-Onn Lui; Catharina Larsson
Journal:  Int J Oncol       Date:  2022-09-28       Impact factor: 5.884

Review 9.  Adrenal Incidentaloma.

Authors:  Mark Sherlock; Andrew Scarsbrook; Afroze Abbas; Sheila Fraser; Padiporn Limumpornpetch; Rosemary Dineen; Paul M Stewart
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871

10.  ELR+ CXC chemokine expression in benign and malignant colorectal conditions.

Authors:  Claudia Rubie; Vilma Oliveira Frick; Mathias Wagner; Jochen Schuld; Stefan Gräber; Brigitte Brittner; Rainer M Bohle; Martin K Schilling
Journal:  BMC Cancer       Date:  2008-06-25       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.